CN102458454A - 用于治疗亨廷顿病的组织激肽释放酶 - Google Patents

用于治疗亨廷顿病的组织激肽释放酶 Download PDF

Info

Publication number
CN102458454A
CN102458454A CN2010800275339A CN201080027533A CN102458454A CN 102458454 A CN102458454 A CN 102458454A CN 2010800275339 A CN2010800275339 A CN 2010800275339A CN 201080027533 A CN201080027533 A CN 201080027533A CN 102458454 A CN102458454 A CN 102458454A
Authority
CN
China
Prior art keywords
klk1
seq
huntington
disease
tissue kallikrein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800275339A
Other languages
English (en)
Chinese (zh)
Inventor
M·威廉姆斯
M·查尔斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanomune Inc
Original Assignee
Sanomune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanomune Inc filed Critical Sanomune Inc
Publication of CN102458454A publication Critical patent/CN102458454A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2010800275339A 2009-04-22 2010-04-22 用于治疗亨廷顿病的组织激肽释放酶 Pending CN102458454A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17157909P 2009-04-22 2009-04-22
US61/171,579 2009-04-22
PCT/CA2010/000575 WO2010121361A1 (en) 2009-04-22 2010-04-22 Tissue kallikrein for the treatment of huntington's disease

Publications (1)

Publication Number Publication Date
CN102458454A true CN102458454A (zh) 2012-05-16

Family

ID=43010630

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800275339A Pending CN102458454A (zh) 2009-04-22 2010-04-22 用于治疗亨廷顿病的组织激肽释放酶

Country Status (6)

Country Link
US (1) US20120225051A1 (https=)
EP (1) EP2421554A4 (https=)
JP (1) JP2012524725A (https=)
CN (1) CN102458454A (https=)
CA (1) CA2759490A1 (https=)
WO (1) WO2010121361A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2182978A4 (en) 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN
US20130315891A1 (en) * 2012-05-25 2013-11-28 Matthew Charles Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
EP2854841B1 (en) 2012-06-04 2017-02-22 Diamedica Inc. Human tissue kallikrein 1 glycosylation isoforms
WO2015109107A1 (en) * 2014-01-15 2015-07-23 Cal Poly Pomona Foundation, Inc. Treatment and diagnosis of huntington's disease
CN110446501A (zh) 2017-03-09 2019-11-12 代阿麦迪卡股份有限公司 组织激肽释放酶1的剂型
CN116549619A (zh) * 2022-01-28 2023-08-08 江苏众红生物工程创药研究院有限公司 激肽原酶及其衍生物在治疗vci、psci或csvd中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056532A2 (en) * 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
US20070191296A1 (en) * 2003-08-30 2007-08-16 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with kallikrein 13 (klk13)
EP1664790A2 (en) * 2003-08-30 2006-06-07 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with kallikrein 8 (klk8)
EP2182978A4 (en) * 2007-07-20 2012-03-21 Sanomune Inc TISSUE KALLIKREIN FOR THE TREATMENT OF DISEASES ASSOCIATED WITH AMYLOID PROTEIN

Also Published As

Publication number Publication date
JP2012524725A (ja) 2012-10-18
EP2421554A1 (en) 2012-02-29
WO2010121361A1 (en) 2010-10-28
EP2421554A4 (en) 2012-11-28
US20120225051A1 (en) 2012-09-06
CA2759490A1 (en) 2010-10-28

Similar Documents

Publication Publication Date Title
JP5955219B2 (ja) 酸性スフィンゴミエリナーゼ欠乏症に対する用量漸増酵素補充療法
TWI250019B (en) Preventing airway mucus production by administration of EGF-R antagonists
US20220401520A1 (en) Methods of treating mild brain injury
CN102458454A (zh) 用于治疗亨廷顿病的组织激肽释放酶
US10314885B2 (en) Oxytocin treatment to modify blood glucose and treat metabolic disease
Zhu et al. Potential of food protein-derived bioactive peptides against sarcopenia: a comprehensive review
AU2010228068A1 (en) Tissue kallikrein for the treatment of pancreatic beta-cell dysfunction
US20180028617A1 (en) Methods of treating mild brain injury and post-traumatic stress disorder
Sukhotnik et al. Oral insulin enhances intestinal regrowth following massive small bowel resection in rat
KR20160091888A (ko) 요법에 사용하기 위한 인슐린-유사 성장 인자 모방체
JP2021502404A (ja) 線維症の治療のための組成物および方法
JP6623463B2 (ja) 頭蓋内圧上昇の治療
US20240000891A1 (en) Growth and differentiation factor 15 for treatment of proliferative vitreoretinopathy therapy
US20070203065A1 (en) Insulin-Independent, Bone Morphogenetic Protein (Bmp)-Mediated Uptake Of Blood Glucose By Peripheral Cells And Tissues
US20090221484A1 (en) Use of Factor VII Polypeptides for Neuroprotection
AU2024293527A9 (en) Method of producing fabp4 inhibitor-loaded biomaterial and application for the treatment of tendon and ligament injuries
KR20250023259A (ko) 근육 감소 억제 효과를 갖는 갈색거저리 유충 단백 가수분해 펩타이드 조성물
JP6192141B1 (ja) 骨量減少抑制剤、及びそれを有効成分とする骨粗鬆症の予防又は改善剤
HK40105076A (zh) 微生物组组合物、组分或代谢物用於治疗眼睛病症的方法和用途
CN118490828A (zh) Oxgr1受体激动剂促进肺黏液纤毛清除系统功能
Iwata et al. Human Parathyroid Hormone (1-34) Transiently Increa Excretion of Lysosomal Enzymes into Urine and the Sit Lysosomes
WO2021101814A1 (en) Intranasal leptin prevents opioid-induced respiratory depression in obesity
JP2001226281A (ja) 抗ストレス剤および抗ストレス食品

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120516